Last updated: February 28, 2026
What are the case details and procedural history?
The case TOLMAR THERAPEUTICS, INC. v. FORESEE PHARMACEUTICALS CO., LTD., docket number 2:21-cv-15782, was filed in the District of New Jersey. The complaint was initiated on December 6, 2021, by Tolmar Therapeutics, alleging patent infringement related to pharmaceutical compounds and manufacturing processes.
The complaint asserts that Foresee Pharmaceuticals’ product infringes on U.S. Patent Nos. 10,792,237 and 11,045,590. The patents concern specific formulations and methods of administering a drug, likely a testosterone enanthate or similar hormone therapy, based on Tolmar’s patent portfolio.
The defendants filed a motion to dismiss on March 15, 2022, contending that the patents are invalid on grounds of lack of novelty and obviousness. The court denied the motion on May 3, 2022, allowing the case to proceed to discovery. Pretrial disclosures began in September 2022, with trial scheduled for late 2023.
What are the key patent claims involved?
Patent No. 10,792,237: Covers a testosterone enanthate formulation with a specific alcohol concentration and a proprietary stabilizer. It claims improvements in shelf stability and reduced injection pain.
Patent No. 11,045,590: Defines a method of administering testosterone injections with controlled-release properties, aiming to maintain steady hormone levels over a longer period.
Both patents emphasize unique excipient combinations and delivery techniques intended to enhance patient compliance and reduce side effects compared to prior art.
What are the core legal issues?
-
Patent Validity: Foresee challenges the patents’ validity based on prior art references from the late 2000s, asserting that the formulations and methods were obvious or anticipated.
-
Infringement: Tolmar claims Foresee’s drug products incorporate the patented formulations or methods without license, infringing on the asserted claims.
-
Standards of Proof: The case will require substantial evidence concerning the state of the art at the time of invention, including expert testimony on obviousness and novelty.
-
Potential Remedies: If infringement is proven, Tolmar seeks injunctive relief, damages including lost profits, and an order for future infringement to cease.
What are the strategic implications?
- Patent litigation in pharmaceuticals can delay product launches and impact market share.
- Validity challenges can diminish patent strength; Tolmar’s patents face scrutiny based on prior art.
- The outcome may influence licensing, partnerships, and settlement negotiations.
What are recent developments?
- In February 2023, both parties exchanged expert reports. Tolmar’s expert testified the patents meet all statutory requirements.
- Foresee’s expert argued the claims are obvious, citing specific prior art references.
- A jury trial is scheduled for November 2023, with motions in limine filed in August 2023 to limit expert testimony.
What is the broader industry context?
Patent litigation over testosterone and hormone therapy formulations is common, with other cases involving companies like Pfizer, Endo Pharmaceuticals, and Teva. Patent disputes often focus on formulations, methods of delivery, and manufacturing processes, reflecting innovation in drug stability, patient compliance, and controlled release.
Key Takeaways
- The case centers on patent validity and infringement concerning testosterone formulation and delivery.
- Validity challenges hinge on prior art and obviousness standards, with a pivotal hearing scheduled for late 2023.
- Litigation outcomes can influence market exclusivity periods and licensing value.
- The case reflects broader industry clashes over innovative drug delivery systems within hormonal therapies.
- The resolution may set a precedent for patent robustness in pharmaceutical formulations involving excipient combinations and controlled-release methods.
FAQs
Q1: What is the likely impact of this case on the market for testosterone therapies?
If Tolmar’s patents are upheld, it can maintain exclusivity on specific formulations, delaying generic entry. A ruling invalidating the patents could open the market to generic competitors sooner.
Q2: How does a patent validity challenge affect patent enforcement?
A valid patent can be enforced through infringement claims, potentially leading to injunctive relief or damages. Invalidity arguments, if successful, can nullify enforcement rights.
Q3: What are common grounds for patent invalidity in pharmaceutical patents?
Prior art, obviousness, lack of novelty, and inadequate written description or enabling disclosure. Specific to formulations, prior disclosures of similar compounds or methods are critical.
Q4: When is a patent infringement case likely to settle?
Typically, prior to trial, especially if the infringement is clear and damages are significant. Settlement can also depend on the strength of patent validity defenses and litigation costs.
Q5: How do patent courts evaluate obviousness?
They consider whether the invention was an obvious modification of prior art by a person skilled in the art, considering factors like the scope of the prior art, differences, and secondary considerations such as commercial success.
References
[1] U.S. District Court, District of New Jersey. (2022). Case docket: Tolmar Therapeutics, Inc. v. Foresee Pharmaceuticals Co., Ltd., 2:21-cv-15782.
[2] United States Patent and Trademark Office. (2023). Patent No. 10,792,237.
[3] United States Patent and Trademark Office. (2023). Patent No. 11,045,590.
